Three companies are set to see their share lock-in periods expire on Wednesday, October 15, potentially increasing the supply of tradable shares in the market. This development could impact the trading dynamics of these stocks.

Companies Affected

Key Highlights

Anthem BioSciences

• The stock has shown positive momentum since its July listing, gaining 8.00% from its initial price of ₹570.00 per share.

Shringar House of Mangalsutra

• The company's ₹400.00 crore IPO was oversubscribed by 60 times, indicating strong investor interest.
• Currently, the stock is trading close to its listing price of ₹188.50.

Dev Accelerator

• Despite the upcoming lock-in expiry, the stock has faced challenges since its September listing, declining 21.00% from its IPO price.

Implications of Lock-in Expiry

It's important to note that while the end of lock-in periods makes these shares eligible for trading, it does not guarantee that they will be sold in the open market. Investors should be aware that increased share availability could potentially impact stock prices, but actual market reactions can vary based on multiple factors.

Market participants will be closely watching these stocks for any significant trading activity or price movements following the lock-in expiry.

Anthem Biosciences , a leading drug discovery and manufacturing services company, has seen its shares soar by 46% since its listing on July 21, with an additional 11% boost following the announcement of robust June-quarter results on August 13. The company's impressive financial performance and ambitious expansion plans have caught investors' attention.

Strong Q1 Financial Results

Anthem Biosciences reported stellar financial results for the first quarter:

The company's operating margin slightly decreased to 38.10% from 39.20%, primarily due to share-based compensation charges of ₹4.40 crore.

Expansion and Growth Strategies

Anthem Biosciences is actively pursuing expansion strategies to capitalize on market opportunities:

1. Capacity Expansion: The company is increasing its production capacity by 155 kilolitres, aiming to reach a total capacity of 425 kilolitres by September 2025. In the June quarter alone, 54 kilolitres were added.

2. Product Portfolio Growth: Two new products received approval, expanding the commercial portfolio from 10 to 12 products.

3. Revenue Projection: Anthem Biosciences expects a 20% annual revenue growth for FY26, showcasing confidence in its business model and market demand.

4. Backward Integration: The company has successfully completed backward integration on a key molecule, potentially improving cost efficiency and supply chain control.

5. GLP-1 Drug Development: Anthem is developing GLP-1 obesity and diabetes drugs, targeting opportunities as patents expire in multiple markets.

Recent Corporate Developments

According to the latest LODR (Listing Obligations and Disclosure Requirements) data, Anthem Biosciences recently conducted a postal ballot through remote e-voting. The company announced on September 15, 2025, that the resolutions set out in the postal ballot notice were approved by the members with the requisite majority. The resolutions are deemed to have been passed on September 12, 2025.

This corporate action demonstrates Anthem Biosciences' commitment to shareholder engagement and transparency in its decision-making processes.

Conclusion

Anthem Biosciences' strong financial performance, coupled with its strategic expansion plans and focus on innovation, has resonated well with investors. The company's efforts in capacity expansion, product portfolio diversification, and development of new drug candidates position it favorably for future growth in the competitive pharmaceutical services sector.

As Anthem Biosciences continues to execute its growth strategy, investors and industry observers will be keenly watching its progress in maintaining this momentum and capitalizing on emerging opportunities in the drug discovery and manufacturing services market.